Abira Medical Laboratories, LLC v. Anthem Blue Cross Blue Shield of Connecticut

CourtDistrict Court, D. Connecticut
DecidedJuly 2, 2025
Docket3:24-cv-00872
StatusUnknown

This text of Abira Medical Laboratories, LLC v. Anthem Blue Cross Blue Shield of Connecticut (Abira Medical Laboratories, LLC v. Anthem Blue Cross Blue Shield of Connecticut) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Abira Medical Laboratories, LLC v. Anthem Blue Cross Blue Shield of Connecticut, (D. Conn. 2025).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT ABIRA MEDICAL LABORATORIES, ) 3:24-CV-00872 (SVN) LLC d/b/a GENESIS DIAGNOSTICS, ) Plaintiff, ) ) v. ) ) ANTHEM BLUE CROSS BLUE SHIELD ) July 2, 2025 OF CONNECTICUT, ABC COMPANIES ) 1-100, AND JOHN DOES 1-100, Defendants. RULING AND ORDER ON DEFENDANT’S MOTION TO DISMISS Sarala V. Nagala, United States District Judge. In this insurance-related action, Plaintiff Abira Medical Laboratories, LLC, alleges that it performed laboratory testing services for insureds of Defendants Anthem Blue Cross Blue Shield of Connecticut (“Anthem” or “Defendant”), ABC Companies 1-100 and John Does 1-100, for which Plaintiff has not been fully compensated. Plaintiff brings claims under state common law, the Families First Coronavirus Response Act (“FFCRA”) and the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, although it also seeks to recover benefits and obtain equitable relief under the Employee Retirement Income Security Act (“ERISA”). Defendant has moved to dismiss the complaint in its entirety under Federal Rules of Civil Procedure 8 and 12(b)(6). For the reasons described below, the motion to dismiss is GRANTED with leave to amend, except as to the equitable estoppel, quantum meruit/unjust enrichment, and FFCRA and CARES Act claims, as well as claims barred by anti-assignment and time limitations provisions, and any state law claims preempted by ERISA and the Federal Employee Health Benefits Act (“FEHBA”)—all of which are dismissed without leave to amend. I. FACTUAL AND PROCEDURAL BACKGROUND Plaintiff initiated this lawsuit on May 14, 2024, Compl., ECF No. 1, and quickly amended its complaint when the Court pointed out that the original complaint alleged that the relevant events took place in Pennsylvania, rather than Connecticut, see Order, ECF No. 9; Am. Compl., ECF No.

10. The amended complaint contains the following allegations, which are accepted as true for the purpose of this motion. Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). Plaintiff operates a laboratory business that performs medical testing services on specimens submitted to it. ECF No. 10 ¶¶ 1, 19. Defendant Anthem is a mutual insurance company that provides health insurance services. Id. ¶¶ 2, 8. The amended complaint also includes unnamed Defendants ABC Companies 1-100 and John Does 1-100. See id. ¶ 12. From approximately February 2016 to October 2020, Plaintiff provided laboratory testing services for Defendants and, specifically, for Defendants’ “insureds/claimants.” See id. ¶¶ 1–2, 30–32. Plaintiff alleges that these services were ordered by “physician members of insurance companies . . . , by a non-member physician, or an insured/patient member of an insurance

company.” See, e.g., id. ¶ 1. An unspecified number of claims relate to testing services related to COVID-19. See id. at ¶¶ 44, 55–56. Plaintiff submitted insurance claims to Defendants to receive payment for the laboratory services performed, which Defendants were “supposed to pay.” Id. ¶ 29; see also id. ¶ 25. Plaintiff alleges that Defendants were required to pay such claims, in part, because Defendants entered into insurance contracts with insureds/claimants that required Defendants to pay for laboratory testing services for these insureds/claimants, and that the insureds/claimants assigned to Plaintiff their rights under these insurance contracts by providing their insurance information to Plaintiff for laboratory testing. Id. ¶¶ 26–27, 36, 43. The amended complaint itself does not specify how many claims are at issue, but alleges that their value is not less than $3,793,084. Id. ¶ 1. Defendants processed and paid 135 claims submitted by Plaintiff, such that Plaintiff alleges that it was induced to render more laboratory services for the insureds/claimants of Defendants. ECF No. 10 ¶ 31. Plaintiff also alleges that

certain “intermittent communication” from Defendants induced this reliance and that Defendants knew that their actions would induce such reliance. Id. Eventually, after Defendants allowed Plaintiff’s claims to grow, Defendants began refusing to pay claims submitted by Plaintiff. Id. Plaintiff alleges that it exhausted administrative remedies concerning the nonpayment of claims by filing appeals when claims were denied. Id. ¶¶ 4, 38. Plaintiff alleges that it may legally recover for the underpaid or unpaid claims, asserting it is a “designated representative” within the meaning of 29 C.F.R. § 2560.503-1(b)(4)1 to secure benefits on behalf of “insureds/claimants,” or that it is otherwise a contract assignee of the contract between Defendant and its insureds, such that it is “in privity” of contract with Defendants. Id. ¶¶ 27, 35–36, 43; see also id. ¶ 37.

Plaintiff brings claims for: breach of contract (Count 1); breach of the implied covenant of good faith and fair dealing (Count 2); fraudulent misrepresentation (Count 3); negligent misrepresentation (Count 4); promissory estoppel (Count 5); equitable estoppel (Count 6); quantum meruit/unjust enrichment (Count 7); and violation of the Families First Coronavirus Response Act (“FFCRA”) and the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act (Count 8). Plaintiff does not bring a claim under ERISA, despite alleging that, “[t]o the extent that the contracts relevant to the underlying claims are governed by ERISA,” Plaintiff’s action “is

1 That section provides, in relevant part: “The claims procedures [under ERISA] do not preclude an authorized representative of a claimant from acting on behalf of such claimant in pursuing a benefit claim or appeal of an adverse benefit determination. Nevertheless, a plan may establish reasonable procedures for determining whether an individual has been authorized to act on behalf of a claimant . . . .” brought to: (1) recover benefits pursuant to 29 U.S.C. § 1132(a)(1)(B), and (2) for equitable relief, pursuant to 29 U.S.C. § 1132(a)(3).” Id. ¶ 34. Defendant first moved to dismiss the amended complaint in July of 2024. See Mot. to Dismiss, ECF No. 19. Following a discovery conference on a motion to stay discovery after the

filing of Defendant’s motion to dismiss, the Court ordered that Plaintiff disclose a list of claims at issue, which included the insureds’ dates of birth. Order, ECF No. 31. Plaintiff’s list of claims identified 3,003 claims at issue in this case (the “Disputed Claims”). See ECF No. 42-1 at 10; Spreadsheet, ECF No. 42-5. Defendant represents it was able to identify 2,445 of the Disputed Claims as claims administered by it. See ECF No. 42 at 11. After receiving this list from Plaintiff, Defendant moved to file an amended motion to dismiss to include materials related to the Disputed Claims. See Mot. for Leave to File Am. Mot. to Dismiss, ECF No. 38. The Court granted this request, and Defendant filed the presently pending amended motion to dismiss, including charts depicting which claims it was able to identify, as well as plan documents for the plans governing the claims at issue. See ECF Nos. 42-2–42-126; see

also ECF No. 46. II. RELIANCE ON MATERIALS OUTSIDE OF THE COMPLAINT Defendant has moved to dismiss the complaint on all counts under Rules 8 and 12(b)(6) of the Federal Rules of Civil Procedure. Am. Mot. to Dismiss, ECF No. 42.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Paneccasio v. Unisource Worldwide, Inc.
532 F.3d 101 (Second Circuit, 2008)
Pilot Life Insurance v. Dedeaux
481 U.S. 41 (Supreme Court, 1987)
Aetna Health Inc. v. Davila
542 U.S. 200 (Supreme Court, 2004)
Empire Healthchoice Assurance, Inc. v. McVeigh
547 U.S. 677 (Supreme Court, 2006)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Faber v. Metropolitan Life Insurance
648 F.3d 98 (Second Circuit, 2011)
Salahuddin v. Cuomo
861 F.2d 40 (Second Circuit, 1988)
Muto v. CBS Corp.
668 F.3d 53 (Second Circuit, 2012)
Rolon v. Henneman
517 F.3d 140 (Second Circuit, 2008)
Dickau v. Town of Glastonbury
242 A.2d 777 (Supreme Court of Connecticut, 1968)
Rahmati v. Mehri
452 A.2d 638 (Supreme Court of Connecticut, 1982)
Monteiro v. American Home Assurance Co.
416 A.2d 1189 (Supreme Court of Connecticut, 1979)
Montefiore Medical Center v. Teamsters Local 272
642 F.3d 321 (Second Circuit, 2011)
Travelers Indemnity Co. of Connecticut v. Losco Group, Inc.
150 F. Supp. 2d 556 (S.D. New York, 2001)
Joslin v. Grossman
107 F. Supp. 2d 150 (D. Connecticut, 2000)
Culver v. Culver
17 A.3d 1048 (Connecticut Appellate Court, 2011)
Heimeshoff v. Hartford Life & Accident Ins. Co.
134 S. Ct. 604 (Supreme Court, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Abira Medical Laboratories, LLC v. Anthem Blue Cross Blue Shield of Connecticut, Counsel Stack Legal Research, https://law.counselstack.com/opinion/abira-medical-laboratories-llc-v-anthem-blue-cross-blue-shield-of-ctd-2025.